Advances in cell therapy for synovial sarcoma are creating more treatment options for patients with advanced disease. A recent update from Penn Medicine highlights the growing role of T-cell therapies in treating rare cancers like synovial sarcoma. What Is Afami-cel? Afamitresgene autoleucel (afami-cel) is the first FDA-approved T-cell receptor (TCR) therapy for adults with advanced […]
UI Health Care Begins Treating Patients With TCR Therapy for Synovial Sarcoma
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Arizona Pioneers New Immune Therapy for Synovial Sarcoma Treatment
In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the state to receive a cutting-edge immune-cell therapy, TECELRA, at the HonorHealth Research Institute in Scottsdale. Synovial sarcoma is a rare soft-tissue cancer that primarily affects large joints in the arms and legs, though it can […]



